Press Release

ALL

2022

2021

2020~2015

Dec 08, 2022

SyneuRx CEO Emil Tsai Named Fellow of National Academy of Inventors

July 31, 2022

SyneuRx Announces Final Results of Phase 2 Clinical Trial of COVID-19 Oral Antiviral Candidate Pentarlandir® (SNB01)

July 25, 2022

Dr. Joseph T. Coyle Named Chair of SyneuRx’s Scientific Advisory Board

Apr 13, 2022

SyneuRx Reaches Target Enrollment in Phase 2 Clinical Trial of COVID-19 Oral Antiviral Candidate Pentarlandir® (SNB01)

Jan 06, 2022

SyneuRx Announces Oral COVID-19 Antiviral Drug Candidate Pentarlandir® Is Showing Effectiveness Against Both the Omicron and Delta COVID-19 Variants